ArticleFrontiers in pharmacology2025
Sedative exposure and mortality in intracranial hypertensive tuberculous meningitis: a cohort study with propensity-score matching and machine learning analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculous meningitis (TBM) complicated by intracranial hypertension requires aggressive neurocritical care, yet the mortality impact of sedative and antipsychotic exposure remains controversial. This study investigates the association between sedative exposure and mortality while identifying modifiable risk factors in this vulnerable population. Methods: In this retrospective cohort study, we analyzed 1,875 intracranial hypertensive TBM patients from the MIMIC-IV database (v2.0). Exposure was stratified by cumulative sedative days (>3 vs. ≤3). Primary outcomes included 200-day mortality assessed using multivariable logistic regression and Cox proportional hazards models. Propensity score matching (PSM) was performed to adjust for confounding, and machine learning (XGBoost) was used to predict mortality and evaluate feature importance. Results: Unadjusted analyses identified age (odds ratio [OR] = 1.03 per year; 95% confidence interval [CI]: 1.01-1.05), sedative duration (OR = 1.13 per day; 95%CI: 1.04-1.22), and hospital length of stay (LOS; OR = 1.02 per day; 95%CI: 1.00-1.03) as significant mortality predictors. In the PSM cohort (n = 160 matched pairs), crude mortality rates were 16% in sedated versus 2.6% in non-sedated patients (p < 0.001), though the adjusted hazard ratio was non-significant (hazard ratio [HR] = 1.12; 95%CI: 0.83-1.50). Survival curves showed 200-day survival rates of 82% (95%CI: 79%-85%) for non-sedated and 47% (95%CI: 39%-55%) for sedated patients. The XGBoost model achieved an AUC-ROC of 0.79, identifying gender (SHAP value = 0.41), age (0.38), and LOS (0.29) as top predictors of mortality. Conclusion: Prolonged sedation (>3 days) is associated with substantially reduced survival in intracranial hypertensive TBM, potentially reflecting both underlying disease severity and iatrogenic effects. Although residual confounding remains, machine learning analysis highlights the critical influence of gender and LOS on outcomes. These findings demonstrate the need for randomized trials evaluating targeted sedation minimization strategies to improve neurotuberculosis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.